Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

finnCap Interim Profit More Than Doubles; Chair To Step Down

Wed, 18th Nov 2020 13:59

(Alliance News) - finnCap Group PLC on Wednesday said profit in the first half of its financial year more than doubled amid increased equity fundraising from clients.

Shares in finnCap were up 12% at 21.80 pence in London in afternoon trading.

The London-based stockbroker reported a GBP3.6 million pretax profit for the six months ended September 30, more than twice the GBP1.4 million profit reported in the prior year.

This came as revenue jumped 44% to GBP20.5 million from GBP14.2 million.

finnCap explained: "Against our initial expectations, activity in our markets in H1 has been strong, with increased equity fundraisings to support our clients' financial needs and investment in strong business cases. We have also benefited from on-going long-term investment in building leading expertise in the healthcare, biotech and tech sectors where there has been significant corporate activity.

"As a result, revenue generation in H1 has proven to be stronger than we expected and, with cost actions outlined above, we have therefore delivered materially higher profits and cashflow than in H1 last year."

The firm raised more than GBP300 million across 15 equity fundraisings for listed clients, plus 2 initial public offerings. It also advised on 4 completed takeovers and public company advisory roles worth GBP212 million total.

finnCap said its financial third quarter has started well with the completion of the Fonix Mobile PLC IPO, which raised GBP45 million, as well as a GBP87 million placing and open offer for Synairgen PLC. It is expecting "a good result" for financial 20201, which ends March 31, "well ahead of the prior year". finnCap also expects its disposal of a 70% holding in PrimaryBid Ltd, for approximately GBP700,000, to complete in early 2021.

Jon Moulton, finnCap's chief executive officer, it to retire at the end of December, succeeded by Robert Lister. Lister, who joins finnCap January 1, "spent 25 years in investment banking first with Barclays de Zoete Wedd where he started as a graduate in 1983 and rose to become head of European Equities in 1998 and then at Dresdner Kleinwort Benson where he was global head of Equities."

Howard Leigh will step down from the board, becoming senior partner of newly integrated Corporate Finance (UK) Ltd.

Chief Executive Sam Smith said: "Our strategy of developing a full suite of products for growth companies - which, we believe, differentiates us from our peers - is delivering incremental revenue. Having completed the integration of Cavendish, we are now moving into a key phase of our strategy - carefully seeking bolt on acquisitions in adjacent sectors which align with our culture and further our vision of building a more broadly-based group, focused on servicing growing companies' needs.

"The uncertain operating environment means we must remain cautious, however, Q3 has started well, with the completion of the IPO of Fonix Mobile and a further large fund raising for Synairgen and our pipeline of deals remains good."

The company declared a 0.5 pence per share interim dividend, having ceased dividend payments in financial 2020.

Additionally, finnCap noted its chief financial officer, Richard Snow, bought 95,364 shares at 22.65 pence each, worth GBP21,600, on Wednesday. Snow now is interested in 328,697 shares, a 0.2% stake.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Sep 2020 19:32

IN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial

IN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial

Read more
8 Sep 2020 15:16

Synairgen upbeat on latest data from SNG001 trials

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced positive data from the interim analysis of its exploratory phase 2 clinical trial of inhaled 'SNG001' on Tuesday, in chronic obstructive pulmonary disease (COPD) patients with a confirmed respiratory viral infection.

Read more
21 Jul 2020 15:51

IN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line

IN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line

Read more
20 Jul 2020 20:23

COVID SCIENCE-Multiple vaccine candidates show early promise; inhaled interferon helps severe COVID-19 patients

By Nancy LapidJuly 20 (Reuters) - The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Early tests of COVID-19 ...

Read more
20 Jul 2020 16:55

LONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News

LONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News

Read more
20 Jul 2020 11:54

Synairgen Shares Soar On Positive Trial Results For Covid-19 Treatment

Synairgen Shares Soar On Positive Trial Results For Covid-19 Treatment

Read more
20 Jul 2020 09:10

REFILE-UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases

(Refiles to correct spelling in the media identifier)* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasmBy Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold ...

Read more
20 Jul 2020 09:10

UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases

* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasm (Recasts, adds comment from CEO and academic expert)By Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold...

Read more
20 Jul 2020 09:10

UPDATE 1-Synairgen shares soar as drug shows lower risk of severe COVID-19 cases

(Adds details on the trial, shares)July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of severe cases in hospitalised patients with COVID-19, according to data from a trial of more than 100 people in the United Kingdo...

Read more
20 Jul 2020 07:56

Europe open: Stocks reverse early losses, healthcare leads

(Sharecast News) - Stocks have recovered from early selling following news that European Union leaders meeting in Brussels had made progress on the terms for a reconstruction fund.

Read more
20 Jul 2020 07:56

Synairgen's drug shows reduced risk of severe disease in COVID-19 patients

July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of developing severe diseases in hospitalised COVID-19 patients, according to data from a trial of more than 100 people in the United Kingdom.The trial, which used in...

Read more
20 Jul 2020 07:20

Synairgen treatment reduces risk of 'severe' Covid-19 by 79%

(Sharecast News) - Synairgen's Covid-19 treatment sharply reduced the risk of patients developing severe forms of the illness provoked by the novel coronavirus, clinical trials showed.

Read more
22 Jun 2020 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
18 Jun 2020 17:59

IN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001

IN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001

Read more
18 Jun 2020 09:12

Synairgen expands Covid-19 trial nationwide

(Sharecast News) - Synairgen is to expand trials of a potential treatment for Covid-19 nationally, the respiratory drug specialist said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.